October 7, 2025 — Leads & Copy — Alloy Therapeutics Inc. and the University of British Columbia (UBC) have announced a collaboration to accelerate the discovery of novel antibody therapeutics for pandemic preparedness applications. Under the agreement, Alloy will contribute its expertise to support UBC discovery efforts in developing antibody therapies for infectious‑disease targets.
UBC researchers will leverage high-throughput cryo-electron microscopy to advance novel antibody therapeutics as part of the Pathogen Response Optimization by GENeratIng ThErapeutics Rationally (PROGENITER) program. PROGENITER is a program in Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), one of five national research hubs.
Sriram Subramaniam, Ph.D., PROGENITER Director, Professor and Gobind Khorana Canada Excellence Research Chair at UBC, stated that the collaboration will advance their mission to develop technologies aimed at generating novel antibody therapies rapidly. Heather Schwoebel, Chief Business Officer, Antibodies, and Head of Strategic Collaborations at Alloy Therapeutics, added that the collaboration underscores Alloy’s flexible and partnership-driven approach to investing in innovation. John-Paul Heale, M.B.A., Ph.D., Managing Director, Innovation UBC, noted UBC’s commitment to working with industry leaders to drive scientific innovation.
As part of the collaboration, Alloy has established a subsidiary in Ontario, Canada, strengthening the company’s global footprint. Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together.
Contact:
Heather Schwoebel, Chief Business Officer, Antibodies, and Head of Strategic Collaborations at Alloy Therapeutics.
Sriram Subramaniam, Ph.D., PROGENITER Director, Professor and Gobind Khorana Canada Excellence Research Chair at UBC.
John-Paul Heale, M.B.A., Ph.D., Managing Director, Innovation UBC.
Source: Alloy Therapeutics
